Lupagen is a privately held early stage biotech company developing first-in-class bedside enabled cell & gene therapies (CAR-T cell, gene editing and immunotherapy products) based on their patent-pending bedside point-of-care C> production and delivery platform. Lupagen’s systems are deployed using standard apheresis-based platform customized for a diverse range of gene therapies that require targeted genetic or cellular modification of selective populations of a patient’s circulating peripheral blood mononuclear cells.